Matches in Wikidata for { <http://www.wikidata.org/entity/Q31157420> ?p ?o ?g. }
- Q31157420 P2860 Q31157420-A7047067-4528-4A9C-AD84-29F987F03DAC @default.
- Q31157420 P2860 Q31157420-AA400641-0505-48E8-B8F5-A0936DCF3D70 @default.
- Q31157420 P2860 Q31157420-B5F81090-9973-4549-B5B8-1D7C1F70271D @default.
- Q31157420 P2860 Q31157420-BCD03B39-5919-4381-B982-7D5A06C0BA13 @default.
- Q31157420 P2860 Q31157420-BDD267DA-8389-498A-84DE-B5D20ED5D078 @default.
- Q31157420 P304 Q31157420-98FD7D81-736D-4BE6-B886-3639D97EF745 @default.
- Q31157420 P31 Q31157420-47433642-BA14-4C7D-8365-79298EE8313E @default.
- Q31157420 P356 Q31157420-B62DF0D4-F54F-498E-8677-6F2B1AF58707 @default.
- Q31157420 P433 Q31157420-E3BF66D5-1064-44BC-8A91-53D8A019C0AC @default.
- Q31157420 P478 Q31157420-8E9C9722-D927-4A3F-BD8D-E2B0F7098744 @default.
- Q31157420 P50 Q31157420-4A79F938-5C10-4613-A38A-1BECEE7BE25E @default.
- Q31157420 P50 Q31157420-60CE11F7-44D9-4454-A883-72A3AF1113C3 @default.
- Q31157420 P50 Q31157420-65049A13-2FC3-42F9-BE40-DDA275D2D9B0 @default.
- Q31157420 P50 Q31157420-918BAAFF-55DF-461A-9A79-7E921982B3E8 @default.
- Q31157420 P50 Q31157420-996E50EA-E599-4031-9735-434954042D4A @default.
- Q31157420 P577 Q31157420-988632A5-C0BA-4D1D-89A3-9D2D9AF099F0 @default.
- Q31157420 P698 Q31157420-BEA04084-648A-46EB-9618-CE79D10ECFA0 @default.
- Q31157420 P921 Q31157420-1112f8c9-bc12-4b8a-a71b-9394ca0794df @default.
- Q31157420 P921 Q31157420-40270703-ED3D-49EF-A991-2F8533EE9942 @default.
- Q31157420 P921 Q31157420-41F1616E-9EB9-48AA-9246-48AF9B7980EB @default.
- Q31157420 P921 Q31157420-8C79185E-5C16-4817-B9FF-2A18334B5CDE @default.
- Q31157420 P921 Q31157420-920B28DD-7DD4-4FEA-8DC3-1558352F9545 @default.
- Q31157420 P921 Q31157420-ECB8F295-1E2E-47B5-B01E-3D41CDEB6B10 @default.
- Q31157420 P356 EUW368 @default.
- Q31157420 P698 28130378 @default.
- Q31157420 P1433 Q2596718 @default.
- Q31157420 P1476 "Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation" @default.
- Q31157420 P2093 "David Callans" @default.
- Q31157420 P2093 "Hussein Al-Khalidi" @default.
- Q31157420 P2093 "Jens Cosedis Nielsen" @default.
- Q31157420 P2093 "Karl Georg Hæusler" @default.
- Q31157420 P2093 "Luigi Di Biase" @default.
- Q31157420 P2860 Q26864604 @default.
- Q31157420 P2860 Q27341873 @default.
- Q31157420 P2860 Q29615678 @default.
- Q31157420 P2860 Q30316734 @default.
- Q31157420 P2860 Q34220185 @default.
- Q31157420 P2860 Q35201917 @default.
- Q31157420 P2860 Q35868819 @default.
- Q31157420 P2860 Q36407198 @default.
- Q31157420 P2860 Q36944900 @default.
- Q31157420 P2860 Q37427004 @default.
- Q31157420 P2860 Q37889006 @default.
- Q31157420 P2860 Q37970932 @default.
- Q31157420 P2860 Q38432008 @default.
- Q31157420 P2860 Q38445460 @default.
- Q31157420 P2860 Q41219727 @default.
- Q31157420 P2860 Q41746599 @default.
- Q31157420 P2860 Q42654303 @default.
- Q31157420 P2860 Q42662461 @default.
- Q31157420 P2860 Q46562359 @default.
- Q31157420 P2860 Q46600826 @default.
- Q31157420 P2860 Q46719193 @default.
- Q31157420 P2860 Q46903146 @default.
- Q31157420 P2860 Q48537715 @default.
- Q31157420 P2860 Q50553600 @default.
- Q31157420 P2860 Q53127204 @default.
- Q31157420 P2860 Q53328204 @default.
- Q31157420 P2860 Q57626863 @default.
- Q31157420 P304 "132-138" @default.
- Q31157420 P31 Q13442814 @default.
- Q31157420 P356 "10.1093/EUROPACE/EUW368" @default.
- Q31157420 P433 "1" @default.
- Q31157420 P478 "19" @default.
- Q31157420 P50 Q38326091 @default.
- Q31157420 P50 Q43472482 @default.
- Q31157420 P50 Q67189332 @default.
- Q31157420 P50 Q74771070 @default.
- Q31157420 P50 Q78700769 @default.
- Q31157420 P577 "2017-01-01T00:00:00Z" @default.
- Q31157420 P698 "28130378" @default.
- Q31157420 P921 Q182338 @default.
- Q31157420 P921 Q186093 @default.
- Q31157420 P921 Q2312472 @default.
- Q31157420 P921 Q414462 @default.
- Q31157420 P921 Q436572 @default.
- Q31157420 P921 Q815819 @default.